Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Sequence, Crossover Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients

NCT03291288 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT03291288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03291288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Sequence, Crossover Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Completed
Start date
February 26, 2018
Completion date
April 16, 2021
Enrollment
32 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

drug interaction potential